Effects of B cell–activating factor on tumor immunity-Reference-Cited by-同舟云学术

Effects of B cell–activating factor on tumor immunity

Published:2020-05-21 Issue:10 Volume:5 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Yarchoan Mark^ORCID,Ho Won Jin^ORCID,Mohan Aditya,Shah Yajas,Vithayathil Teena,Leatherman James,Dennison Lauren,Zaidi Neeha,Ganguly Sudipto^ORCID,Woolman Skylar,Cruz Kayla^ORCID,Armstrong Todd D.,Jaffee Elizabeth M.^ORCID

Funder

National Cancer Institute

The Commonwealth Foundation for Cancer Research

The Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care

The Bloomberg~Kimmel Institute for Cancer Immunotherapy

National Institutes of Health

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/136417/files/pdf

Reference54 articles.

1. Reciprocal regulation of polarized cytokine production by effector B and T cells

2. Cytokine-producing B lymphocytes—key regulators of immunity

3. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors.

4. B Cells Drive Early T Cell Autoimmunity In Vivo prior to Dendritic Cell-Mediated Autoantigen Presentation

5. B Cells Are the Dominant Antigen-Presenting Cells that Activate Naive CD4+ T Cells upon Immunization with a Virus-Derived Nanoparticle Antigen

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors;Journal for ImmunoTherapy of Cancer;2024-04

2. Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis;Frontiers in Immunology;2024-02-06

3. B cell-targeted polylactic acid nanoparticles as platform for encapsulating jakinibs: potential therapeutic strategy for systemic lupus erythematosus;Nanomedicine;2023-11

4. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank;Frontiers in Immunology;2023-10-12

5. Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap;Expert Opinion on Therapeutic Targets;2023-09-02